Posters

Clinical evaluation of a new hydrophobic aspheric IOL material with blue light filter

Poster Details

First Author: M.Holzer GERMANY

Co Author(s):    S. Laupp   T. Rabsilber                 

Abstract Details

Purpose:

Monofocal hydrophobic IOLs are one of the most common lenses which are implanted during cataract surgery. Glistening formation following the implantation of such lenses can occur and might influence the quality of vision. A new glistening free hydrophobic material as well as a new injector device were developed and used for a new monofocal, blue light filtering, aspheric IOL.

Setting:

Retrospective, single-center study. Eye Center Prof. Dr. Holzer & Prof. Dr. Rabsilber, Weinheim/Mannheim, Germany.

Methods:

One hundred eyes following cataract surgery and routine implantation of a new monofocal hydrophobic aspheric IOL (Clareon AutonoMe, Alcon Inc.) were included in this investigation. IOL power calculation accuracy and refractive outcomes as well as slit lamp findings were analyzed 1 day, 1 week and 3 months postoperatively.

Results:

All surgeries were uneventful with normal IOL unfolding and no postoperative IOL related complications. IOL power calculation using the SRK/T formula showed a median deviation from intended refraction of 0.44 D. 81.1% of eyes achieved postoperatively a CDVA of 20/25 or better whereas the preop maximum CDVA was 20/25 in 13.5% of the eyes. Median CDVA improved from 0.25 logMAR to 0.10 logMAR postoperatively. No IOL haze or glistening was noticed postoperatively. All IOLs remained optical clear without glistening or haze formation.

Conclusions:

The new monofocal hydrophobic aspheric IOL showed good functional outcomes and a precise IOL power calculation. Slit lamp examinations showed clear IOLs with no glistening formation during the follow-up period.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a competing company